Results From A Phase I Pharmacokinetic (Pk) And Safety Study Of Trph-222, A Novel Cd22-Targeting Antibody-Drug Conjugate, In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R Nhl)
TRPH-222
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Results From A Phase I Pharmacokinetic (Pk) And Safety Study Of Trph-222, A Novel Cd22-Targeting Antibody-Drug Conjugate, In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R Nhl) ### Output: TRPH-222